Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Prior treatment

• Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis)

Other illness

• Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
• A known hypersensitivity to any components of the ORKA-002 drug product

Age

• History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence

Other

• Women who are breastfeeding or plan to breastfeed during the study

• Participants ≥ 18 and \< 80 years of age at the time of consent
• Have a diagnosis of plaque psoriasis for \> 6 months
• Have moderate-to-severe chronic plaque psoriasis defined as:
  • BSA ≥ 10%, and
  • PASI ≥ 12, and
  • IGA score of ≥ 3 on a 5-point scale
• Candidate for systemic therapy or phototherapy
• Women of childbearing potential must have a negative pregnancy test